Continuous Subcutaneous Insulin Infusion strAtegy Versus Multiple Daily Insulin Injections strAtegy (CAMACS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01574508 |
Recruitment Status : Unknown
Verified May 2013 by Guang Ning, Shanghai Jiao Tong University School of Medicine.
Recruitment status was: Recruiting
First Posted : April 10, 2012
Last Update Posted : May 6, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Type 2 Diabetes | Drug: Transient Continuous Subcutaneous Insulin Infusion Drug: Transient Multiple Daily Insulin Injections | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 120 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Study Start Date : | December 2011 |
Estimated Primary Completion Date : | December 2013 |
Estimated Study Completion Date : | December 2014 |

Arm | Intervention/treatment |
---|---|
Experimental: Continuous Subcutaneous Insulin Infusion
CSII
|
Drug: Transient Continuous Subcutaneous Insulin Infusion
Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
Other Name: CSII |
Active Comparator: Multiple Daily Insulin Injections
MDI
|
Drug: Transient Multiple Daily Insulin Injections
Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
Other Name: MDI |
- Glycated hemoglobin levels [ Time Frame: During 2 weeks intensive insulin treatment period and 1 year after the intensive treatment. ]The different influence of two intensive insulin treatment strategies: CSII and MDI on the change of glycated hemoglobin levels during two weeks intensive insulin treatment period and 1 year after the intensive treatment.
- Glycated albumin levels [ Time Frame: During 2 weeks intensive insulin treatment period and 1 year after the intensive treatment. ]The different influence of two intensive insulin treatment strategies: CSII and MDI on the change of glycated albumin levels during two weeks intensive insulin treatment period and 1 year after the intensive treatment.
- The glucose levels [ Time Frame: During 2 weeks intensive treatment and 1 year after treatment ]The different influence of CSII and MDI on the change of plasma glucose levels during 2 weeks intensive treatment and 1 year after treatment
- Episode of hypoglycemia [ Time Frame: During 2 weeks of intensive treatment and 1 year after treatment ]The different influence of CSII and MDI on Episode of hypoglycemia during 2 weeks of intensive treatment and 1 year after treatment
- Body weight [ Time Frame: During 2 weeks intensive treatment and 1 year after treatment ]The different influence of CSII and MDI on Body weight during 2 weeks intensive treatment and 1 year after treatment
- Biochemical parameters and inflammatory factors [ Time Frame: During 2 weeks intensive treatment and 1 year after treatment ]The different influence of CSII and MDI on the change of biochemical parameters and inflammatory factors during 2 weeks intensive treatment and 1 year after treatment
- C peptide levels [ Time Frame: During 2 weeks intensive treatment and 1 year after treatment ]The different influence of CSII and MDI on the change of C peptide levels during 2 weeks intensive treatment period and 1 year after treatment
- Number of participants with adverse events [ Time Frame: During 2 weeks intensive treatment and 1 year after treatment ]The number of Participants with adverse events in different intensive treatment strategies (CSII or MDI) during 2 weeks intensive treatment period and 1 year after treatment.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 25 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Using at least two kinds of oral hypoglycaemic agents, one of which must be insulin secretagogues (at least half of the maximum permitted daily dose); or at least two kinds of oral hypoglycaemic agents, one of which must be insulin secretagogues (at least half of the maximum permitted daily dose), plus once daily basic insulin treatment (daily dosage < 30IU);
- The anti-diabetic therapy is stable within 3 months before study screening;
- Age: 25-65years, both gender, BMI: 20-35kg/m2;
- Good compliance with the follow-up
- Signed informed consent
- HbA1c ≥ 8.0 % and ≤ 12%
Exclusion Criteria:
- Having the history of using insulin therapy twice daily or MDI or insulin pump (except the insulin therapy during gestational diabetes mellitus)
- For once daily insulin therapy: daily dose insulin therapy dosage > 30IU
- Having the history of using GLP-1 for therapy within 3 months before screening
- Women in pregnancy or under breast feeding
- Having acute diabetic complications within 6 months before screening or having severe chronic diabetic complications at screening
- Allergic to study drugs
- Severe liver dysfunction, including serum alanine aminotransferase concentration more than 2.5 times above upper limit of normal range, abnormal renal function (GFR < 60ml/min)
- Other severe conditions which will put the patients in high risk during the study
- Recently drug or alcohol abuse

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01574508
China, Shanghai | |
Ruijin hospital, Shanghai Jiao-Tong University School of Medicine | Recruiting |
Shanghai, Shanghai, China, 200025 | |
Contact: Guang Ning, Professor 8621-64370045 ext 665344 feifei1116@hotmail.com | |
Principal Investigator: Guang Ning, Professor |
Responsible Party: | Guang Ning, Professor, Shanghai Jiao Tong University School of Medicine |
ClinicalTrials.gov Identifier: | NCT01574508 |
Other Study ID Numbers: |
CCEMD012 |
First Posted: | April 10, 2012 Key Record Dates |
Last Update Posted: | May 6, 2013 |
Last Verified: | May 2013 |
efficacy safety intensive insulin therapy |
Insulin Insulin, Globin Zinc Hypoglycemic Agents Physiological Effects of Drugs |